Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

05/02/2014 Award for the T-Systems Data Center located in the Barcelona Synchrotron Park 27/01/2014 Companies from the Barcelona Synchrotron Park will have a privileged access to the ICMAB scientific equipments 20/01/2014 The Catalan Institute of Nanoscience and Nanotechnology opens its new building 14/01/2014 Barcelona, the 4th smartest city in Europe 03/01/2014 The Vall d’Hebron Institut de Recerca becomes a UAB-affiliated research institute 28/11/2013 Visit of a Moscow City Council delegation at Barcelona Synchrotron Park (BSP)
43 44 45 46 47 48 49